- Treatment and investigation of epileptiform disorders
- Basic mechanisms of seizure generation
- Medical and interventional management of cerebrovascular disease
- Medical education
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
J Clin Oncol. 2019 Jun 07;:JCO1802238
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2019 May 07;:
Can J Neurol Sci. 2018 Dec 17;:1-7
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Lancet Oncol. 2018 Jul 16;:
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
Gynecol Oncol. 2016 Apr 23;
Neurocognitive and Seizure Outcomes of Selective Amygdalohippocampectomy versus Anterior Temporal Lobectomy for Mesial Temporal Lobe Epilepsy.
Epilepsy Res Treat. 2014;2014:306382
Parietal lobe source localization and sensitivity to hyperventilation in a patient with subclinical rhythmic electrographic discharges of adults (SREDA).
Clin Neurophysiol. 2006 Oct;117(10):2257-63
Neurology. 2005 Apr 12;64(7):1311-2